News & Updates

Show Multimedia Only

High-fat dairy ups risk of liver disease mortality, cancer

21 Jul 2025

Individuals who regularly consume high-fat dairy are at greater risk of death due to chronic liver diseases (CLD), reveals a recent study. However, low-fat dairy intake may lower such risk.

High-fat dairy ups risk of liver disease mortality, cancer

21 Jul 2025

Hepatic steatosis linked to lower mortality in CLD patients

16 Jul 2025

The presence of substantial hepatic steatosis estimated by controlled attenuated parameter (CAP) score among patients who underwent vibration-controlled transient elastography (VCTE) appears to reduce the risk of all-cause mortality and decompensation, particularly in those with metabolic dysfunction-associated steatotic liver disease (MASLD), reports a study.

Hepatic steatosis linked to lower mortality in CLD patients

16 Jul 2025

SGLT-2 inhibitors may provide liver-related benefits to patients with cirrhosis

09 Jul 2025 by

The use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitor helps lower the incidence of serious liver events among patients with cirrhosis who are receiving diuretic therapy, according to a study.

SGLT-2 inhibitors may provide liver-related benefits to patients with cirrhosis

09 Jul 2025

CDK4/6 inhibitor-induced liver injury common in breast cancer

05 Jul 2025 by

Liver injury occurs in around one in 20 patients treated with cyclin-dependent kinase 4/6 inhibitors for metastatic breast cancer, according to a multicentre retrospective study in Spain.

CDK4/6 inhibitor-induced liver injury common in breast cancer

05 Jul 2025

ALT helps spot liver fibrosis in overweight children

05 Jul 2025

Alanine aminotransferase (ALT) appears to be a useful primary screening measure to identify early signs of fibrosis, such as increased liver stiffness, in children with overweight or obesity and additional risk factors, according to a study.

ALT helps spot liver fibrosis in overweight children

05 Jul 2025

FMT prevents hepatic encephalopathy recurrence in cirrhosis

30 Jun 2025 by

A phase II study has demonstrated the safety of faecal microbiota transplantation (FMT) in patients with cirrhosis treated with lactulose and rifaximin, with no related adverse events (AEs) seen. FMT also results in lower rates of hepatic encephalopathy (HE) recurrence.

FMT prevents hepatic encephalopathy recurrence in cirrhosis

30 Jun 2025

Diabetes in CHD patients ups risk of hepatocellular carcinoma

26 Jun 2025 by

The presence of diabetes mellitus predisposes patients with chronic hepatitis B (CHB) to a higher risk of developing hepatocellular carcinoma (HCC), reveals a study presented at EASL 2025.

Diabetes in CHD patients ups risk of hepatocellular carcinoma

26 Jun 2025

Injectable extended-release naltrexone poses no hepatotoxicity signal in advanced ALD

24 Jun 2025

The use of the injectable extended-release naltrexone for alcohol use disorder in patients with advanced alcohol-associated liver disease (ALD) does not appear to carry a substantial hepatotoxicity or liver decompensation risk, according to a study.

Injectable extended-release naltrexone poses no hepatotoxicity signal in advanced ALD

24 Jun 2025

Carvedilol trumps propranolol in preventing decompensation in cirrhosis

23 Jun 2025

A recent study has provided data bolstering the current recommendation of using carvedilol to prevent a first decompensation of cirrhosis in patients with compensated cirrhosis.

Carvedilol trumps propranolol in preventing decompensation in cirrhosis

23 Jun 2025

Metabolic burden ups risk of death in CHB patients with SLD

23 Jun 2025

Metabolic burden in patients with chronic hepatitis B (CHB) and concurrent steatotic liver disease (SLD) may exacerbate the risks of all-cause, liver-related, and cardiovascular mortality, suggests a study.

Metabolic burden ups risk of death in CHB patients with SLD

23 Jun 2025

News & Updates

Showing Hepatology articles

Showing

Specialty:

High-fat dairy ups risk of liver disease mortality, cancer

High-fat dairy ups risk of liver disease mortality, cancer

Hepatic steatosis linked to lower mortality in CLD patients

Hepatic steatosis linked to lower mortality in CLD patients

SGLT-2 inhibitors may provide liver-related benefits to patients with cirrhosis

SGLT-2 inhibitors may provide liver-related benefits to patients with cirrhosis

CDK4/6 inhibitor-induced liver injury common in breast cancer

CDK4/6 inhibitor-induced liver injury common in breast cancer

ALT helps spot liver fibrosis in overweight children

ALT helps spot liver fibrosis in overweight children

FMT prevents hepatic encephalopathy recurrence in cirrhosis

FMT prevents hepatic encephalopathy recurrence in cirrhosis

Diabetes in CHD patients ups risk of hepatocellular carcinoma

Diabetes in CHD patients ups risk of hepatocellular carcinoma

Injectable extended-release naltrexone poses no hepatotoxicity signal in advanced ALD

Injectable extended-release naltrexone poses no hepatotoxicity signal in advanced ALD

Carvedilol trumps propranolol in preventing decompensation in cirrhosis

Carvedilol trumps propranolol in preventing decompensation in cirrhosis

Metabolic burden ups risk of death in CHB patients with SLD

Metabolic burden ups risk of death in CHB patients with SLD